Current structural understanding of kinases is largely based on x-ray crystallographic studies, whereas very little data exist on the conformations and dynamics that kinases adopt in the solution state. ABL kinase is an important drug target in the treatment of chronic myelogenous leukemia. Here, we present the first characterization of ABL kinase in complex with three clinical inhibitors (imatinib, nilotinib, and dasatinib) by modern solution NMR techniques. Structural and dynamical results were derived from complete backbone resonance assignments, experimental residual dipolar couplings, and (15)N relaxation data. Residual dipolar coupling data on the imatinib and nilotinib complexes show that the activation loop adopts the inactive confo...
The improper activation of the Abl tyrosine kinase results in chronic myeloid leukemia (CML). The re...
Inhibitors that bind competitively to the ATP binding pocket in the kinase domain of the oncogenic f...
Abl kinase inhibitors targeting the ATP binding pocket are currently used as a front-line therapy fo...
Successful treatment of chronic myelogenous leukemia (CML) is based on tyrosine kinase inhibitors (T...
Dasatinib is a second-generation BCR-ABL inhibitor approved for the treatment of patients with chron...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Imatinib (Glivec or Gleevec) potently inhibits the tyrosine kinase activity of BCR-ABL, a constituti...
The physiological activity of Abelson tyrosine kinase (Abl) is linked to many cellular processes, su...
Allosteric inhibitors of Bcr-Abl have emerged as a novel therapeutic option for the treatment of CML...
The positions of the P-loop and the activation loop are indicated in yellow. Imatinib binds and stab...
Abl kinase inhibitors targeting the ATP binding pocket are currently employed as potent anti-leukemo...
<div><p>Chronic myeloid leukemia (CML) is caused by the kinase activity of the BCR-Abl fusion protei...
Computational chemistry lets us model intermolecular interactions in ways assays cannot. My project ...
The c-Abl protein-tyrosine kinase regulates diverse cellular signaling pathways involved in cell gro...
The improper activation of the Abl tyrosine kinase results in chronic myeloid leukemia (CML). The re...
The improper activation of the Abl tyrosine kinase results in chronic myeloid leukemia (CML). The re...
Inhibitors that bind competitively to the ATP binding pocket in the kinase domain of the oncogenic f...
Abl kinase inhibitors targeting the ATP binding pocket are currently used as a front-line therapy fo...
Successful treatment of chronic myelogenous leukemia (CML) is based on tyrosine kinase inhibitors (T...
Dasatinib is a second-generation BCR-ABL inhibitor approved for the treatment of patients with chron...
Quantifying binding specificity and drug resistance of protein kinase inhibitors is of fundamental i...
Imatinib (Glivec or Gleevec) potently inhibits the tyrosine kinase activity of BCR-ABL, a constituti...
The physiological activity of Abelson tyrosine kinase (Abl) is linked to many cellular processes, su...
Allosteric inhibitors of Bcr-Abl have emerged as a novel therapeutic option for the treatment of CML...
The positions of the P-loop and the activation loop are indicated in yellow. Imatinib binds and stab...
Abl kinase inhibitors targeting the ATP binding pocket are currently employed as potent anti-leukemo...
<div><p>Chronic myeloid leukemia (CML) is caused by the kinase activity of the BCR-Abl fusion protei...
Computational chemistry lets us model intermolecular interactions in ways assays cannot. My project ...
The c-Abl protein-tyrosine kinase regulates diverse cellular signaling pathways involved in cell gro...
The improper activation of the Abl tyrosine kinase results in chronic myeloid leukemia (CML). The re...
The improper activation of the Abl tyrosine kinase results in chronic myeloid leukemia (CML). The re...
Inhibitors that bind competitively to the ATP binding pocket in the kinase domain of the oncogenic f...
Abl kinase inhibitors targeting the ATP binding pocket are currently used as a front-line therapy fo...